$MRVI

Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.

Maravai LifeSciences (MRVI) reported Q2 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink at $34.7 million and Cygnus at $16.8 million. Adjusted EBITDA was $8.7 million, and GAAP net loss was $21.6 million. Full-year guidance: revenue $205-$215 million and adjusted EBITDA $33-$35 million.

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Second quarter 2026 total revenue up 9% from prior year SAN DIEGO, Calif., — August 6, 2026 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents a

Biotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The filing indicates they had briefly exceeded 5% beneficial ownership on May 6, 2026, but were below that threshold by the filing date, with a Joint Filing Agreement dated May 11, 2026. This is a passive investment disclosure, as indicated by the use of Schedule 13G.

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -33.33% and -18.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai ( MRVI ) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai ( MRVI ) To Contact Him Directly To Discuss Their Options

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -33.33% and -2.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings ...